ViroXis Gets Approval To Initiate FDA Phase 2 Study For Molluscum Contagiosum

TFS Corporation Limited announced that its pharmaceutical partner ViroXis has received Institutional Review Board approval to initiate Federal Drug Administration phase 2 study for the treatment of molluscum contagiosum using TFS's East Indian sandalwood oil. IRB approval is a prerequisite to initiate clinical studies in the United States for prescription drugs.

Frank Wilson, CEO of TFS, said. "This is another important milestone in the development of a global market for TFS's pharmaceutical grade EISO in the dermatology sector. It builds on the exclusive supply agreement with a leading global dermatology company for over the counter dermatology products, which are expected to launch in the United States later this year."

Molluscum contagiosum is a very prevalent and highly contagious pox virus skin infection.

23 March 2014